Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

McGill University

$150,000.00

Clinical validation of an innovative multiplex antibody microarray platform

EF 2009-10

Résumé
Early diagnosis of cancer, and many other diseases, significantly increases chance of survival. However, simple-to-perform blood based tests are largely missing. For breast cancer for example screening, diagnosis, staging, or routine surveillance cannot be performed as a blood test. There are indications that by measuring a panel of proteins it may be possible to "fingerprint" the disease and the patient with much more accuracy, and thus help early diagnosis and disease management. We invented a novel technology for measuring many proteins accurately in blood. We will validate this technology and demonstrate that it may be used for measuring multiple proteins that can serve as biomarkers for breast cancer and other diseases. This technology may then be used to validate biomarkers for cancer, cardiovascular and infectious diseases, and eventually as a diagnostic tool for use in the clinic.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
195144
Name
Juncker David
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Clinical validation of an innovative multiplex antibody microarray platform
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Antibody Microarrays; Biomarkers; Breast Cancer; Microfluidics; Serum
Abstract
Early diagnosis of cancer, and many other diseases, significantly increases chance of survival. However, simple-to-perform blood based tests are largely missing. For breast cancer for example screening, diagnosis, staging, or routine surveillance cannot be performed as a blood test. There are indications that by measuring a panel of proteins it may be possible to "fingerprint" the disease and the patient with much more accuracy, and thus help early diagnosis and disease management. We invented a novel technology for measuring many proteins accurately in blood. We will validate this technology and demonstrate that it may be used for measuring multiple proteins that can serve as biomarkers for breast cancer and other diseases. This technology may then be used to validate biomarkers for cancer, cardiovascular and infectious diseases, and eventually as a diagnostic tool for use in the clinic.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Juncker, David
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~